Vericel (VCEL) Other Non-Current Assets (2019 - 2026)
Vericel's (VCEL) quarterly Other Non-Current Assets came in at $288000.0 in Q1 2026, down 42.51% year-on-year from $501000.0 in Q1 2025, and down 15.54% quarter-over-quarter from $341000.0 in Q4 2025.
Vericel (VCEL) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Vericel has disclosed Other Non-Current Assets across 8 years of filings, most recently posting $288000.0 for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $288000.0, down 42.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $288000.0 (down 42.51% YoY), and the FY2025 annual result was $341000.0, down 38.67% from the prior year.
- Other Non-Current Assets came in at $288000.0 for Q1 2026 at Vericel, down from $341000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $43.0 million in Q2 2023 to a low of $288000.0 in Q1 2026.
- The 5-year median for Other Non-Current Assets is $717000.0 (2024), against an average of $3.9 million.
- Across the five-year window, Other Non-Current Assets jumped 2830.81% in 2022 and tumbled 98.46% in 2024, its largest moves.
- Vericel's Other Non-Current Assets stood at $1.3 million in 2022, then plunged by 40.83% to $771000.0 in 2023, then decreased by 27.89% to $556000.0 in 2024, then slumped by 38.67% to $341000.0 in 2025, then decreased by 15.54% to $288000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $288000.0 (Q1 2026), $341000.0 (Q4 2025), and $395000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 288,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 288,000.00 |
| Dec 31, 2025 | 341,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 501,000.00 |
| Dec 31, 2024 | 556,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 664,000.00 |
| Mar 31, 2024 | 717,000.00 |
| Dec 31, 2023 | 771,000.00 |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 43.00 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 6.18 Mn |
| Mar 31, 2022 | 6.18 Mn |
| Dec 31, 2021 | 211,000.00 |
| Sep 30, 2021 | 211,000.00 |
| Jun 30, 2021 | 211,000.00 |